Contineum Therapeutics (CTNM) Competitors $5.77 +0.07 (+1.23%) Closing price 04:00 PM EasternExtended Trading$5.78 +0.02 (+0.26%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTNM vs. KMDA, PRTC, ERAS, RGNX, SNDL, AQST, CMPS, TECX, MBX, and CMPXShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Kamada (KMDA), PureTech Health (PRTC), Erasca (ERAS), REGENXBIO (RGNX), SNDL (SNDL), Aquestive Therapeutics (AQST), COMPASS Pathways (CMPS), Tectonic Therapeutic (TECX), MBX Biosciences (MBX), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Its Competitors Kamada PureTech Health Erasca REGENXBIO SNDL Aquestive Therapeutics COMPASS Pathways Tectonic Therapeutic MBX Biosciences Compass Therapeutics Contineum Therapeutics (NASDAQ:CTNM) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Which has higher valuation & earnings, CTNM or KMDA? Kamada has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum TherapeuticsN/AN/A-$42.26M-$1.97-2.93Kamada$160.95M2.76$14.46M$0.2926.62 Do analysts recommend CTNM or KMDA? Contineum Therapeutics currently has a consensus price target of $22.50, suggesting a potential upside of 289.95%. Kamada has a consensus price target of $13.00, suggesting a potential upside of 68.39%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Contineum Therapeutics is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Kamada 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media refer more to CTNM or KMDA? In the previous week, Contineum Therapeutics and Contineum Therapeutics both had 1 articles in the media. Kamada's average media sentiment score of 1.89 beat Contineum Therapeutics' score of 0.93 indicating that Kamada is being referred to more favorably in the news media. Company Overall Sentiment Contineum Therapeutics Positive Kamada Very Positive Which has more risk & volatility, CTNM or KMDA? Contineum Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Kamada has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Is CTNM or KMDA more profitable? Kamada has a net margin of 9.60% compared to Contineum Therapeutics' net margin of 0.00%. Kamada's return on equity of 6.31% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -24.59% -23.49% Kamada 9.60%6.31%4.43% Do insiders and institutionals have more ownership in CTNM or KMDA? 20.4% of Kamada shares are held by institutional investors. 11.3% of Contineum Therapeutics shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryKamada beats Contineum Therapeutics on 11 of the 15 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$149.28M$3.04B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-2.9321.1828.1120.03Price / SalesN/A337.65460.63103.88Price / CashN/A43.2336.5559.01Price / Book0.758.368.655.90Net Income-$42.26M-$55.19M$3.25B$258.66M7 Day Performance32.64%5.89%4.20%2.23%1 Month Performance25.71%17.63%10.83%12.77%1 Year Performance-72.59%5.10%34.67%19.36% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics3.3655 of 5 stars$5.77+1.2%$22.50+289.9%-73.0%$149.28MN/A-2.9331KMDAKamada4.1156 of 5 stars$7.72-1.1%$13.00+68.5%+33.7%$445.07M$160.95M26.69360News CoveragePRTCPureTech Health2.7843 of 5 stars$18.43-0.4%$45.00+144.2%-16.2%$443.17M$4.83M0.00100Positive NewsUpcoming EarningsERASErasca2.901 of 5 stars$1.52+1.3%$4.57+200.8%-45.0%$429.18MN/A-2.44120RGNXREGENXBIO4.1758 of 5 stars$8.53+4.5%$31.63+270.8%-33.1%$425.76M$156.72M-2.73370News CoveragePositive NewsSNDLSNDL1.8885 of 5 stars$1.64+3.7%$4.00+144.2%-30.8%$420.45M$671.81M-5.522,516News CoverageUpcoming EarningsGap UpAQSTAquestive Therapeutics1.7091 of 5 stars$4.30+2.3%$10.14+136.2%+24.6%$420.06M$54.23M-7.17160CMPSCOMPASS Pathways1.9044 of 5 stars$4.44-0.4%$17.00+282.9%-37.0%$418.21MN/A-2.25120Upcoming EarningsTECXTectonic Therapeutic2.6311 of 5 stars$22.42+2.3%$80.33+258.3%+31.1%$416.62MN/A-3.05120MBXMBX Biosciences2.1249 of 5 stars$12.45+2.1%$37.57+201.8%N/A$416.30MN/A0.0036News CoverageCMPXCompass Therapeutics3.025 of 5 stars$3.06+1.8%$12.67+314.6%+230.9%$414.85M$850K-7.5720Positive News Related Companies and Tools Related Companies KMDA Competitors PRTC Competitors ERAS Competitors RGNX Competitors SNDL Competitors AQST Competitors CMPS Competitors TECX Competitors MBX Competitors CMPX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTNM) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTNM Stock Alerts